SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline
Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.
Zacks Investment Research11/6/2026Negative
SRPT
Sarepta Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.86B
P/E Ratio
—
EPS
$-1.57
Beta
0.45
52W High
$24.68
52W Low
$14.68
50-Day MA
$19.20
200-Day MA
$18.67
Dividend Yield
—
Profit Margin
-5.86%
Forward P/E
17.73
PEG Ratio
159.25
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $1.96B |
| Gross Profit (TTM) | $-411.10M |
| EBITDA | $23.76M |
| Operating Margin | -2.37% |
| Return on Equity | -8.05% |
| Return on Assets | -0.16% |
| Revenue/Share (TTM) | $18.58 |
| Book Value | $14.26 |
| Price-to-Book | 1.21 |
| Price-to-Sales (TTM) | 0.95 |
| EV/Revenue | 1.069 |
| EV/EBITDA | 16.91 |
| Quarterly Earnings Growth (YoY) | 2664.00% |
| Quarterly Revenue Growth (YoY) | -4.50% |
| Shares Outstanding | $105.63M |
| Float | $102.08M |
| % Insiders | 4.88% |
| % Institutions | 103.48% |
Historical Volatility
HV 10-Day
56.55%
HV 20-Day
62.53%
HV 30-Day
54.03%
HV 60-Day
64.23%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($21.64 target)
7
Buy12
Hold3
Sell2
Strong SellLatest News
Sarepta Therapeutics Q3 Earnings Call Highlights
Sarepta Therapeutics NASDAQ: SRPT raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued strength in its exon-skipping drug franchise.
MarketBeat11/6/2026Positive
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research10/29/2026Neutral
Sarepta Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9, 2026:8th Annual Wolfe Research Healthcare Conference in New York CityGuggenheim Securities 3rd Annual Healthcare Innovation Conference in BostonFireside chat: 3 p.m. ETThe presentation from the Guggenheim conference will be webcast live under the in.
Business Wire10/26/2026Neutral
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) demonstrating that SRP-1003, the company's investigational small interfering RNA (siRNA) program for the treatment of myotonic dystrophy type 1 (DM1), can directly reduce pathogenic DMPK transcripts within the nucleus, where the molecular drivers o.
Business Wire10/14/2026Neutral
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima, Japan. Data at WMS includes a late-breaking poster presentation on delandistrogene moxeparvovec efficacy and safety in older, ambulatory Duchenne patients in Sarepta'.
Business Wire9/25/2026Neutral
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat.
MarketBeat9/15/2026Positive
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/14/2026Neutral
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapies for the tough-to-treat rare disease.
Reuters9/8/2026Negative
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne and five to siblings of individuals living with Duchenne. Now in its ninth year, the program was created to recognize individuals living with Duchenne muscular dystrop.
Business Wire9/8/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SRPT and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026